MDM2 and liposarcoma: In addition to CDK inhibitors, MDM2 inhibitors such as milademetan are the possible considerable candidates for the targeted treatments of certain types of sarcomas including liposarcomas, and clinical trials of milademetan has been on-going, showing that the disease control rate and median progression-free survival were 58.5% (95% CI, 44.1 to 71.9) and 7.2 months overall (n=53), and 62.0% (95% CI, 35.4 to 84.8) and 7.4 months against dedifferentiated liposarcomas with the recommended intermittent schedule (n=16), respectively 39.